Insight by Psychology

Surgical innovations face weaker centralized pre‑approval than drugs because techniques vary with operator skill, sham‑control trials are ethically and practically difficult, and regulators developed strict pathways for repeatable pharmaceuticals but not for procedures.

Incrementalist thinking protected psychosurgery because critics targeted procedural details and proponents offered refinements, which reframed problems as solvable tweaks rather than reasons to abandon the underlying, weak rationale.

Relying on an intraoperative 'disorientation yardstick' biased surgeons toward larger lesions because observing immediate drowsiness or confusion was mistaken for therapeutic benefit, so operators increased destruction until that sign appeared.

Without institutional review boards, physicians could rapidly experiment on vulnerable patients because there were no formal consent, control, or long‑term follow‑up requirements to block high‑risk surgical trials.

Theatrical self‑promotion turned a technical operation into a spectacle because carnival‑style exhibits, press courting, and dramatic storytelling made lobotomy compelling to journalists and the public despite weak supporting evidence.

The structural forces that enabled lobotomy can recur today because desperate patients, media hype, economic incentives, and weak vetting still align to let premature, harmful interventions scale before proper evidence accumulates.

The arrival of antipsychotic drugs outcompeted lobotomy because medications like chlorpromazine were safer, cheaper, and reversible, so clinicians shifted toward pharmacological treatments that covered the same use cases without permanent brain destruction.

Territorial conflicts among neurologists, neurosurgeons, and psychiatrists shaped psychosurgery because letting psychiatrists perform transorbital lobotomies threatened neurosurgeons’ turf and provoked backlash that altered how the procedure was practiced and judged.